Herantis Pharma is a clinical-stage biotechnology company based in Finland, focused on developing disease-modifying therapies for neurodegenerative diseases. Its lead candidate, HER-096, is being developed for Parkinson’s disease (PD) and has been designed to target the underlying biology of the condition, rather than just its symptoms.
There are four key reasons why Herantis may be considered a compelling investment opportunity:
1. HER-096 represents a differentiated approach to PD.
Current treatments for PD primarily address symptoms, with limited impact on disease progression. HER-096 has been designed as a potentially disease-modifying therapy, targeting the unfolded protein response pathway, which is linked to the underlying cause of neurodegeneration. This approach aims to restore cellular balance and slow, or even stop, disease progression, positioning the candidate at the forefront of innovation in a space with significant unmet need.
2. Early clinical data provide encouraging validation of the programme.
HER-096 has successfully completed a Phase Ib trial, demonstrating a favourable safety and tolerability profile in patients, alongside confirmed penetration of the blood-brain barrier, a key requirement for a therapy targeting the central nervous system. Biomarker analyses have shown meaningful biological activity across multiple Parkinson’s-related pathways, supporting confidence in the translation from preclinical research to human studies. Collectively, the clinical data to date have laid a robust foundation for subsequent development efforts.
3. Upcoming milestones provide catalysts for value creation.
Herantis is progressing towards a Phase II proof-of-concept trial, which is expected to represent the first real test of efficacy for HER-096. In parallel, the company is actively pursuing partnering opportunities with pharmaceutical companies to support later-stage development and subsequent commercialisation. Recent grant funding, including €8m from Horizon Europe, and equity financing have improved the company’s operating runway, supporting near-term activities and strengthening the company’s position in partnering and regulatory discussions.
4. The programme addresses a sizeable and growing commercial opportunity.
PD affects more than 10 million people globally, and current treatment options remain limited to symptomatic relief. The global market for Parkinson’s therapeutics is projected to grow meaningfully over the next decade, driven by a larger patient population and increased demand for disease-modifying treatments. Should HER-096 demonstrate clinical efficacy in future studies, it could capture a meaningful share of this expanding market.
In summary, Herantis presents a focused and differentiated investment case centred on a novel approach to PD, supported by encouraging early data, clear upcoming catalysts and a potentially large, growing market opportunity. For more information on Herantis, please visit the Edison website.
Published 26 May 2026
